论文部分内容阅读
目的:探讨选择性内皮素A受体拮抗剂BQ-123对人喉癌Hep-2细胞裸鼠种植瘤的生长及血管形成的影响。方法:将实验动物裸鼠随机分为3组:BQ-123[n=8,2mg/(kg.day)]、氟尿嘧啶组[n=8,2mg/(kg.day)]、生理盐水组(n=8),比较各组裸鼠成瘤体积、微血管密度(MVD)。结果:BQ-123组肿瘤体积为(1.62±0.53)cm3,明显小于生理盐水组及氟尿嘧啶组,差异具有统计学意义;BQ-123组的肿瘤组织中MVD高倍镜下为23.2,明显低于生理盐水组(58.6)及氟尿嘧啶组(39.5),差异具有统计学意义。结论:BQ-123对人喉癌Hep-2细胞在裸鼠体内有明显抑瘤作用,肿瘤的体积、肿瘤组织MVD显著低于对照组,表明BQ-123可通过抑制肿瘤血管生成而显著抑制肿瘤生长。
Objective: To investigate the effect of selective endothelin A receptor antagonist BQ-123 on the growth and angiogenesis of human laryngeal carcinoma Hep-2 cells in nude mice. Methods: Nude mice were randomly divided into 3 groups: BQ-123 [n = 8,2mg / (kg.day)], fluorouracil group [n = 8,2mg / (kg.day)], n = 8). The tumor volume and microvessel density (MVD) of nude mice in each group were compared. Results: The volume of tumor in BQ-123 group was (1.62 ± 0.53) cm3, which was significantly lower than that in saline group and fluorouracil group, the difference was statistically significant. The tumor size in BQ-123 group was 23.2 at MVD high magnification, Saline group (58.6) and fluorouracil group (39.5), the difference was statistically significant. CONCLUSION: BQ-123 can significantly inhibit human laryngeal carcinoma Hep-2 cells in nude mice. The volume of tumor and the MVD in tumor tissue were significantly lower than that in control group, indicating that BQ-123 can significantly inhibit tumor growth by inhibiting tumor angiogenesis Grow.